Shares of some top pharmaceuticals companies were mixed at the close of trading:

Shares of some top pharmaceuticals companies are mixed at noon:

Shares of some top pharmaceuticals companies are down at 10 a.m.:

Top doctors at the helm of one of the nation's most influential medical journals are giving the Supreme Court some unsolicited legal advice about a major case.

Vermont and 46 states are urging the U.S. Supreme Court to uphold a Vermont Supreme Court ruling that forced a drug manufacturer to pay $6.8 million to a woman whose arm had to be amputated after she was injected with one of its medications.

Wyeth on Thursday extended a partnership with drug developer Karo Bio of Sweden, through which the companies collaborate to develop drugs to treat the artery disease atherosclerosis.

A new groundbreaking research that could potentially lead to cure Alzheimer's disease and on how Chesapeake's CEO hopes to move Americans away from "expensive imported oil" to natural gas. Following are today's top videos:

Baxter researchers unveiled positive mid-stage test results on an intravenous drug, Wednesday, which is already in late-stage development in a very small number of patients.

Inconclusive test results for a new Alzheimer's drug caused an unjustified sell-off in stocks for pharmaceutical companies Elan and Wyeth, said Elan CEO Kelly Martin.

Keenly awaited details on Elan and Wyeth's new Alzheimer's drug bapineuzumab show it raised the risk of a potentially serious side effect, especially in people with a genetic risk of the disease, the companies said on Tuesday.

Wyeth Tuesday said its first-quarter net profit fell slightly, hurt by the sudden launch early this year of a generic form of its Protonix ulcer drug, but surprisingly strong sales enabled the company to beat Wall Street profit forecasts.

Ahead of the weekend, CNBC asks the experts where investors should place their bets.